Market Overview

Morgan Stanley Maintains on Allscripts Healthcare Solutions

Related MDRX
Goldman Says These 25 Healthcare Stocks Are Immune To The Election
Allscripts Posts Its Sixth Straight Quarter Of New Order Growth

In a report published Wednesday, Morgan Stanley analyst Julie Murphy maintained an Overweight rating on Allscripts Healthcare Solutions (NASDAQ: MDRX), raising its price target to $20.00 from $17.00.

According to the report, following the previous Morgan Stanley note “What a Difference a Year Makes! Turnaround Thesis Validated” published this morning, analysts are updating model estimates and price target for MDRX.

“Our PT is based on a 2.7x EV/Sales multiple, the 2-yr avg FY1 multiple for MDRX pre-April 2012 (prior to the strategic alternatives upheaval seen that year) applied to our base case 2015 revenue est of $1,523M,” the report noted. “Our bull case valuation of $23 reflects a 2.9x EV/Sales multiple (3-yr avg multiple pre-April 2012) applied to our bull case 2015 revenue estimate of $1607M. Our bear case valuation of $14 is based on a 2.0x multiple (3-yr avg multiple) applied to our bear case 2015 revenue estimate of $1,471M.”

MDRX closed Tuesday at $15.52 with shares trading up at 2.51 percent.

Latest Ratings for MDRX

Oct 2016UBSInitiates Coverage onBuy
Sep 2016Cowen & Co.DowngradesOutperformMarket Perform
Aug 2016Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for MDRX
View the Latest Analyst Ratings

Posted-In: Julie Murphy Morgan StanleyAnalyst Color Price Target Analyst Ratings


Related Articles (MDRX)

View Comments and Join the Discussion!